Source link : https://newshealth.biz/health-news/lebrikizumab-shows-cost-benefits-in-atopic-dermatitis-care/
TOPLINE: The introduction of lebrikizumab, a novel monoclonal antibody targeting interleukin-13 for severe atopic dermatitis (AD), was associated with cost savings of approximately €3.3 million over 3 years for the Italian National Healthcare System, according to a budget impact analysis model. The adoption of lebrikizumab increased from 1198 patients in year 1 to 5849 patients […]
The post Lebrikizumab Shows Cost Benefits in Atopic Dermatitis Care first appeared on News Health.
—-
Author : News Health
Publish date : 2025-07-17 12:00:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8